A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients With AD & HV
Latest Information Update: 12 Aug 2014
At a glance
- Drugs Flutafuranol F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors AstraZeneca
- 12 Aug 2014 New trial record